A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

Current treatment options include surgery and chemotherapy, but chemotherapy’s benefits are often modest and can cause substantial side effects.

A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells." In this ...

University of Queensland researchers have found that a genetic mutation that causes melanoma can lie dormant in healthy skin, a finding that could improve screening of areas more prone to the disease.

This recent readout follows successful data from another combination including Braftovi in mCRC.

Ipsen receives CHMP’s positive opinion on Ojemda for treating monotherapy of children with relapsed or refractory BRAF-altered paediatric low-grade glioma: Paris Wednesday, Marc ...

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with ...